Scripta Insightscompanies developing pharmacy navigation solutions for self-insured employers, health plans and members have entered into a strategic partnership with RXSavecard. RXSaveCard offers costs and payment options for pharmacies’ profit costs.
The purpose of this partnership is to help self-insured employers perform their fiduciary duties and reduce the costs of prescription drugs by providing members with affordable medication options, whether covered by a medical plan or cash payment alternative.
In a statement, Scripta explained that it will integrate RXSavecard into the RX navigation platform.
It aims to help members save on high-cost specialty drugs, including GLP-1.
For self-insured employers, the goal is to reduce planned spending by avoiding traditional pharmacy benefits manager (PBM) markup.
Additionally, Scripta will guide members to the most cost-effective medication options available.
It means drugs covered through health plans, converting them into cheaper alternatives or using cash payment sources like RXSavecard.
Scripta said RXSavecard allows Plan Sponsors to provide low-cost or non-cost medications to their members without the need for a switch to a new PBM.
Additionally, employers provide monthly funding for prepaid digital cards that cover all or part of the target drug costs.
Members can use their cards at over 65,000 pharmacies. Mark Cuba Cost Plus Drug and Rely Direct, employer-funded amounts were automatically applied at checkout.
According to Scripta, members can search for discounted RXSaveCard prices and pharmacy alternatives and access the cards directly in the Scripta Members app. Scripta provides clients with detailed reporting on savings.
“RxSavecard shares our commitment to innovating traditional pharmacy benefits models and bringing patients back to control of prescribing options,” Scripta Insights CEO Eric Levin said in a statement.
“By integrating RxSavecard’s national discount network with Scripta Savings Mapper, it makes it even easier for members to compare all options, including new cash pay alternatives, and save money with prescriptions.”
Bigger trends
In May, Scripta Insights launched the GLP-1 Navigator, a tool for the Scripta member app that provides patients with information about GLP-1 medications in a centralized guide.
Updated weekly Scripta’s GLP-1 Navigator helps members understand their options and trade-offs, whether or not their plans cover GLP-1.
In 2024, Scripta Insights announced that it had raised $17 million in Series B funding led by Aquiline, increasing its total funding back then to $42 million.
Contour Venture Partners, Eastside Partners and Remy Investors participated in the round.
In 2023, Scripta Insights collaborated with the Mark Cuban Cost Plus Drug Company.
In a statement, the company said the relationship has encouraged Scripta’s mission to get the right drugs at the best price for its members.
In 2024, RxSavecard raised $1.7 million in seed funding to promote growth and increase consumer access to affordable drugs.
According to BusinessWire, the round was led A distributed venture with participation from industry insiders.
